EchoIQ Limited (AU:EIQ)
ASX:EIQ
Top Page
EchoIQ Limited
(Sydney:EIQ)
Select Model
Select Model
Rating:48Neutral
Price Target:
AU$0.89
â–¼(-1.56% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by very weak financial performance (shrinking revenue, negative gross profit, large operating losses, and ongoing cash burn), partially offset by strong technical momentum with overbought risk. Valuation contributes modestly negatively because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Conservative balance sheet
Zero or negligible debt materially reduces near-term solvency risk and interest burden, giving management time and optionality to pursue restructuring, product investment or selective funding. A low-leverage capital structure supports durability through continued operating losses and financing cycles.
Negative Factors
Declining revenue
Sustained top-line decline erodes scale economics and market position, making it harder to spread fixed costs and invest in product or sales. Continued revenue contraction increases reliance on external funding and hinders the path to sustainable margins over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Zero or negligible debt materially reduces near-term solvency risk and interest burden, giving management time and optionality to pursue restructuring, product investment or selective funding. A low-leverage capital structure supports durability through continued operating losses and financing cycles.
Read all positive factors
EchoIQ Limited (EIQ) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$589.12M
Dividend YieldN/A
Average Volume (3M)2.50M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth127.89%
EPS Growth-107.34%
CountryAU
EmployeesN/A
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-1.34
Shares Outstanding658,237,730
10 Day Avg. Volume1,343,747
30 Day Avg. Volume2,496,323
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.66
Price to Sales (P/S)1270.57
P/FCF Ratio-19.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.60Price Target Upside-33.33% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.60M
EchoIQ Limited Business Overview & Revenue Model
Company Description
Echo IQ Limited provides cardiac diagnostics support solution in Australia. The company offers artificial intelligence-assisted diagnostics technology that enhance the diagnosis of structural heart disease, as well as Aortic Stenosis. It primarily...
How the Company Makes Money
null...
EchoIQ Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.91K | 101.41K | 44.50K | 107.33K | 251.10K | 441.98K |
| Gross Profit | -9.09M | -3.14M | -2.88M | -7.01M | -3.19M | -1.75M |
| EBITDA | -15.58M | -12.74M | -4.81M | -7.66M | -5.85M | -3.14M |
| Net Income | -15.71M | -13.26M | -5.41M | -8.27M | -5.99M | -2.99M |
Balance Sheet | ||||||
| Total Assets | 17.99M | 23.37M | 8.26M | 10.38M | 10.23M | 10.93M |
| Cash, Cash Equivalents and Short-Term Investments | 11.21M | 6.62M | 2.12M | 3.28M | 2.41M | 3.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.83K |
| Total Liabilities | 718.61K | 615.41K | 1.49M | 3.00M | 2.21M | 1.10M |
| Stockholders Equity | 17.27M | 22.76M | 6.77M | 7.38M | 8.02M | 9.84M |
Cash Flow | ||||||
| Free Cash Flow | -8.34M | -6.54M | -3.92M | -5.28M | -2.95M | -2.43M |
| Operating Cash Flow | -8.28M | -6.51M | -3.92M | -4.94M | -2.58M | -1.43M |
| Investing Cash Flow | -2.06M | -11.55M | 0.00 | -59.81K | -367.33K | -1.00M |
| Financing Cash Flow | 16.21M | 22.56M | 2.77M | 5.88M | 1.55M | 2.77M |
EchoIQ Limited Technical Analysis
Positive
0.90
Price Trends
0.57
Positive
0.41
Positive
0.31
Positive
Market Momentum
0.05
Negative
74.44
Negative
93.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EIQ, the sentiment is Positive. The current price of 0.9 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.57, and above the 200-day MA of 0.31, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 74.44 is Negative, neither overbought nor oversold. The STOCH value of 93.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:EIQ.
EchoIQ Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | AU$101.31M | 15.19 | 11.24% | ― | 10.40% | -32.96% | |
48 Neutral | AU$589.12M | -4.87 | -78.48% | ― | 127.89% | -107.34% | |
42 Neutral | AU$31.39M | -1.84 | -62.57% | ― | -38.03% | -11.27% | |
40 Underperform | AU$48.93M | -37.50 | -16.92% | ― | 4.16% | -0.74% | |
39 Underperform | AU$8.83M | -0.46 | 783.67% | ― | -4.90% | -52.78% |
* Technology Sector Average
AU:EIQ
EchoIQ Limited
0.90
0.60
203.39%
AU:UBN
Urbanise.com
0.62
0.11
21.57%
AU:HPG
hipages Group Holdings Ltd.
0.74
-0.32
-30.19%
AU:AR9
archTIS Ltd.
0.07
<0.01
8.33%
AU:PRO
Prophecy International Holdings Ltd
0.11
-0.40
-78.22%
EchoIQ Limited Corporate Events
Echo IQ Deepens Mayo Clinic Pact Ahead of Potential EchoSolv HF FDA Clearance
Mar 23, 2026
Echo IQ has expanded its agreement with Mayo Clinic’s non-profit Mayo Foundation to allow resale and distribution of its EchoSolv HF heart failure decision support software via the Mayo Clinic Platform – Solutions Studio, contingent on...
Echo IQ Issues New Shares Following Option and Performance Right Exercises
Mar 17, 2026
Echo IQ has expanded its quoted share capital on the ASX by issuing 1.2 million fully paid ordinary shares from the exercise of unlisted options and a further 1.625 million shares from the exercise of vested performance rights. The company confirm...
EchoIQ seeks ASX quotation for 1.2 million new ordinary shares
Mar 17, 2026
EchoIQ Limited has applied for quotation on the ASX of 1.2 million new ordinary fully paid shares, with an issue date of March 16, 2026, under its existing ticker EIQ. The newly quoted securities arise from the exercise or conversion of existing o...
EchoIQ Director Increases Stake After Performance Rights Vesting
Mar 13, 2026
EchoIQ Limited has reported a change in the interests of director Steve Formica, reflecting the conversion of performance rights into ordinary shares via related party entities Stevsand Investments Pty Ltd and Formica Investments Pty Ltd. Followin...
EchoIQ Seeks ASX Quotation for 1.63 Million New Shares
Mar 13, 2026
EchoIQ Limited has applied for quotation of 1,625,000 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of March 11, 2026. The additional securities arise from the exercise or conversion of existing options o...
EchoIQ Added to S&P/ASX All Ordinaries in March 2026 Rebalance
Mar 10, 2026
EchoIQ Limited has been added to the SP/ASX All Ordinaries Index as part of SP Dow Jones Indices’ March 2026 quarterly rebalance, effective before the market opens on March 23, 2026. The inclusion places EchoIQ alongside a broad group of eme...
Echo IQ lodges interim financial report for half-year 2025
Feb 26, 2026
Echo IQ Limited has released its consolidated interim financial report for the half-year ended 31 December 2025, providing stakeholders with updated financial information and corporate disclosures. The report includes details of the company’...
Echo IQ posts wider half-year loss as revenues fall and asset backing weakens
Feb 26, 2026
Echo IQ Limited reported a 10.4% year-on-year decline in revenue from ordinary activities to $90,909 for the half-year ended 31 December 2025, alongside a widened after-tax loss of $8.66 million, up 39.3% from the prior corresponding period. The c...
EchoIQ Director Increases Indirect Shareholding via Performance Rights Conversion
Feb 20, 2026
EchoIQ Limited has disclosed a change in director Steve Formica’s indirect interests, reflecting the conversion of performance rights into fully paid ordinary shares. Formica, through related party entities, increased his indirect holding by...
Echo IQ issues 1.63m shares on performance rights exercise
Feb 20, 2026
Echo IQ Limited has issued 1,625,000 fully paid ordinary shares following the exercise of vested performance rights, adding to its existing class of quoted securities on the Australian Securities Exchange. The company confirmed that the issuance w...
EchoIQ seeks ASX quotation for 1.63 million new shares
Feb 20, 2026
EchoIQ Limited, listed on the ASX under ticker EIQ, has disclosed the issue of additional ordinary fully paid shares, though the announcement provides no detail on its core business activities or strategic focus. The company is registered in Austr...
EchoIQ issues 5 million unquoted options under employee incentive scheme
Feb 20, 2026
EchoIQ Limited has notified the market of a new issue of unquoted options as part of its employee incentive scheme. The company has created a new class of options, exercisable at $0.55 and expiring on 19 February 2028, with a total of 5 million op...
EchoIQ issues 4 million unquoted performance rights under staff incentive plan
Feb 20, 2026
EchoIQ Limited has notified the market of the issue of 4,000,000 new performance rights under its employee incentive scheme, with the rights classified as unquoted securities not intended for listing on the ASX. The move underscores the company...
Echo IQ Ties Executive Incentives to Revenue Milestones in Cardiology AI Push
Feb 20, 2026
Echo IQ has granted a total of 4,000,000 performance rights to key executives, including CEO Dustin Haines and U.S. Head of Commercial Nick Lubbers, to align leadership incentives with the company’s commercial growth in cardiology AI. The ri...
EchoIQ Director Increases Shareholding Through Performance Rights Conversion
Feb 6, 2026
EchoIQ Limited has reported a change in director Steve Formica’s indirect interests in the company’s securities, reflecting internal equity adjustments rather than a market transaction. The change arose from the vesting and subsequent ...
Echo IQ Issues New Shares on Exercise of Performance Rights
Jan 30, 2026
Echo IQ Limited has issued 2,225,000 fully paid ordinary shares following the exercise of performance rights, expanding its quoted share capital on the ASX. The company confirmed the issuance was conducted without a prospectus under the Corporatio...
EchoIQ Seeks ASX Quotation for 2.2 Million New Shares
Jan 30, 2026
EchoIQ Limited has applied for quotation on the ASX of 2,225,000 new fully paid ordinary shares under code EIQ, with the securities issued on 30 January 2026 following the exercise or conversion of existing options or other convertible securities....
Echo IQ Issues 1.28 Million New Shares via Option Exercise
Jan 23, 2026
Echo IQ Limited has issued 1,275,000 fully paid ordinary shares following the exercise of unlisted options priced at $0.25 and expiring on 14 June 2027, with the new shares forming part of its existing class of securities quoted on the ASX. The co...
EchoIQ Seeks ASX Quotation for 1.28 Million New Ordinary Shares
Jan 23, 2026
EchoIQ Limited has applied for quotation on the ASX of 1,275,000 new ordinary fully paid shares under its ticker EIQ, with an issue date of 22 January 2026. The additional securities, issued following the exercise or conversion of existing options...
EchoIQ Advances US Push With Strong Heart Failure AI Validation and FDA Filing
Jan 23, 2026
EchoIQ Limited reported major progress in commercialising its AI-powered heart failure diagnostic platform in the US during the December 2025 quarter, highlighted by the clinical validation of EchoSolv HF through the Mayo Clinic Platform’s V...
EchoIQ Director Steve Formica Sees Lapse of 625,000 Performance Rights
Jan 5, 2026
EchoIQ Limited has disclosed a change in the interests of director Steve Formica, whose holdings are held indirectly through related party entities Stevsand Investments Pty Ltd and Formica Investments Pty Ltd. While the number of fully paid ordina...
EchoIQ Announces Lapse of 1.6 Million Performance Rights
Jan 5, 2026
EchoIQ Limited has notified the market of changes to its issued capital, confirming that 1,625,000 performance rights expiring on 31 March 2028, trading under the ASX code EIQAAP, have ceased. The securities lapsed on 31 December 2025 because the ...
EchoIQ Options Lapse as 30 Million Securities Expire Unexercised
Jan 2, 2026
EchoIQ Limited has confirmed that 30 million options, exercisable at $0.25 and due to expire on 31 December 2025 under the ASX code EIQAAH, have lapsed unexercised, resulting in the cessation of these securities. The expiry reduces the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.